
Results
45
High return on equity, past performance and sound balance sheet.
45 companies
Harmony Biosciences Holdings
Market Cap: US$2.1b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$37.27
7D
2.1%
1Y
-0.5%
Global Industrial
Market Cap: US$1.2b
Through its subsidiaries, operates as an industrial distributor of various industrial and maintenance, repair, and operation (MRO) products in the United States and Canada.
GIC
US$32.68
7D
6.9%
1Y
36.6%
Applied Industrial Technologies
Market Cap: US$10.7b
Distributes industrial motion, power, control, and automation technology solutions in the United States, Canada, Mexico, Australia, New Zealand, Singapore, and Costa Rica.
AIT
US$291.74
7D
12.0%
1Y
11.2%
Pegasystems
Market Cap: US$6.5b
Develops, markets, licenses, hosts, and supports enterprise software in the United States, rest of the Americas, the United Kingdom, rest of Europe, the Middle East, Africa, and the Asia-Pacific.
PEGA
US$40.12
7D
-8.2%
1Y
-23.9%
Vita Coco Company
Market Cap: US$3.2b
Develops, markets, and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific.
COCO
US$58.96
7D
10.5%
1Y
57.1%
Market Cap: US$13.1b
Operates as a visual search and discovery platform in the United States, Canada, Europe, and internationally.
PINS
US$19.60
7D
-11.4%
1Y
-51.0%
ResMed
Market Cap: US$38.9b
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.
RMD
US$271.63
7D
5.2%
1Y
14.6%
Stride
Market Cap: US$3.6b
Provides proprietary and third-party online curriculum, software systems, and educational services in the United States and internationally.
LRN
US$87.83
7D
3.8%
1Y
-38.3%
ACADIA Pharmaceuticals
Market Cap: US$4.0b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$23.56
7D
-6.2%
1Y
27.0%